2-Acetyl-4-methylcyclopentanon | 52034-97-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Acetyl-4-methylcyclopentanon
• 英文别名: 2-Acetyl-4-methylcyclopentanone；2-acetyl-4-methylcyclopentan-1-one
• CAS: 52034-97-6
• 化学式: C₈H₁₂O₂
• 分子量: 140.182
• InChiKey: MLNPHZNNPCQQMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Acetyl-4-methylcyclopentanon 、 三氯乙醛 生成 2-(2',2'-Dichlorvinyl)-4-methylcyclopent-2-en-1-on
  参考文献：
  名称：

  Chemistry of .alpha.-haloaldehydes. V. Reaction of .alpha.-haloaldehydes with .alpha.-acetylcyclopentanones in the presence of base

  摘要：

  DOI：

  10.1021/jo00935a008
• 作为产物：
  描述：

  乙酰氯 、 4-(4-Methyl-cyclopent-1-enyl)-morpholine 生成 2-Acetyl-4-methylcyclopentanon
  参考文献：
  名称：

  Chemistry of .alpha.-haloaldehydes. V. Reaction of .alpha.-haloaldehydes with .alpha.-acetylcyclopentanones in the presence of base

  摘要：

  DOI：

  10.1021/jo00935a008

文献信息

• METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING ELCTROPHILE-MEDIATED TOXICITIES
  申请人：MONTEFIORE MEDICAL CENTER

  公开号：US20160074339A1

  公开（公告）日：2016-03-17

  Methods and compositions using 1,3-dicarbonyl compounds are disclosed for treating toxicity due to therapeutic agents and agents that causes oxidative cellular damage and for treating liver ischemia-reperfusion injury, as well as diseases and disorders that are improved through administration of N-acetylcysteine.
• [EN] PYRROLE AND PYRAZOLE DAAO INHIBITORS<br/>[FR] INHIBITEURS DAAO DE PYRROLE ET DE PYRAZOLE
  申请人：SEPRACOR INC

  公开号：WO2005066135A2

  公开（公告）日：2005-07-21

  Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: (I) wherein R1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5; or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR6R7)n; R3 is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium , sodium , zinc ion or a mixture thereof; Z is N or CR4; R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5; R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R6 and R7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R1, R2 and R4 is other than hydrogen; and at least one of X and Y is (CR6R7)n. D-serine or cycloserine may be coadministered along with the compound of formula (I).
• Chemistry of .alpha.-haloaldehydes. V. Reaction of .alpha.-haloaldehydes with .alpha.-acetylcyclopentanones in the presence of base
  作者：Akira Takeda、Sadao Tsuboi、Fumitaka Sakai、Mamoru Tanabe

  DOI：10.1021/jo00935a008

  日期：1974.10